摘要
心力衰竭(HF)的高致残率和死亡率日益引起关注。自卡托普利上市以来,血管紧张素转化酶抑制剂(ACEI)逐渐成为临床HF的一线治疗药物。目前对HF病理生理过程已有较为深入的了解。本文综述ACEI在HF治疗中的应用。
Heart failure(HF) for its high morbidity and mortality has been concerned increasingly.Since captopril approved in 1981,angiotensin converting enzyme inhibitor(ACEI) has become the first-line treatment of HF.With the understanding of pathophysiological process,new therapeutic strategies are becoming the hope of the therapy for HF.This review describes the application progress of ACEI in the treatment of HF.
出处
《世界临床药物》
CAS
2013年第4期249-252,共4页
World Clinical Drug
基金
国家"重大新药创制"科技重大专项(2009ZX0901-007)
